Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Turkmenistan has been showing an upward trend in recent years.
Customer preferences: Turkmenistan has a growing aging population, and with age comes an increased risk of developing blood clots. As a result, there is a growing demand for anti-coagulants in the country. Additionally, there is a rising prevalence of cardiovascular diseases, which further increases the demand for anti-coagulants.
Trends in the market: The Anti-Coagulants market in Turkmenistan is expected to grow due to the rising demand for these drugs. The market is dominated by multinational companies, and the competition is expected to intensify as more players enter the market. The market is also moving towards more advanced and effective anti-coagulants, such as direct oral anticoagulants (DOACs), which are expected to gain popularity due to their ease of use and lower risk of bleeding complications.
Local special circumstances: Turkmenistan has a state-controlled healthcare system, which limits the availability and accessibility of healthcare services and drugs. This has resulted in a shortage of anti-coagulants in the country, which has led to an increase in their prices. Additionally, there is a lack of awareness about the importance of anti-coagulants in preventing blood clots among the general population, which has resulted in a lower demand for these drugs.
Underlying macroeconomic factors: Turkmenistan is a developing country with a growing economy. However, the country heavily relies on its natural gas exports, which makes it vulnerable to fluctuations in the global energy market. The healthcare sector in Turkmenistan is underfunded, which limits the government's ability to invest in healthcare infrastructure and services. This has resulted in a shortage of healthcare professionals and inadequate healthcare facilities in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
